Open Access Review Article

September-October 2026, Vol. 02 (5), 60-75

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND MEDICINAL PLANTS

(An International Peer Reviewed Journal)

Polymeric Nanoparticles for Drug Delivery

Kaviya Priya K*, Ms. Subashini R, Ms. Kamali M.L. , Sri Priya E and Naresh Kannan S

Department of Biotechnology, KIT-Kalaignarkarunanidhi Institute of Technology, Coimbatore, Tamil Nadu, India

ARTICLE INFO:

Received: 09th Oct. 2026; **Received** in revised form: 16th Oct. 2026; **Accepted:** 27th Oct. 2026; **Available online:** 30th Oct. 2026.

Keywords: Polymeric nanoparticles, Drug delivery, Stimuli-responsive, Theranostics, 3D Printing, AI Optimization, Green synthesis, Precision medicine.

DOI: https://doi.org/10.61280/774vgk83

***Corresponding Author:** Kaviya Priya K

Email: kit.26.22bbt025@gmail.com

ABSTRACT

Polymeric nanoparticles (PNPs) have emerged as a revolutionary platform in drug delivery, offering precise control over therapeutic release, enhanced targeting, and improved pharmacokinetics. This review comprehensively examines recent advancements in PNP design, focusing on smart stimuli-responsive systems that enable on-demand drug release in response to pH, redox potential, or external triggers like light and ultrasound .Green synthesis approaches using biodegradable, eco-friendly polymers and solvent-free techniques are addressing sustainability challenges in nanomedicine .We highlight breakthroughs in theranostic nanoparticles, which combine therapy and diagnostics through integrated imaging agents, facilitating real-time treatment monitoring. Innovations in 3D printing and AI-driven optimization are transforming PNP fabrication, allowing for personalized medicine through predictive modeling of drug-polymer interactions and release kinetics. .Despite these advancements, critical hurdles remain in scalability, long-term biocompatibility, and regulatory approval, limiting widespread clinical adoption. Future research must focus on enhancing tumor penetration, optimizing stealth coatings to evade immune clearance, and developing biohybrid systems such as cell-mimicking nanoparticles. The integration of machine learning and autonomous feedback mechanisms promises to user in a new era of precision drug delivery, while multi-drug-loaded PNPs could revolutionize combination therapies for cancer and infectious diseases. As the field progresses toward clinically viable solutions, polymeric nanoparticles stand at the forefront of next-generation nanomedicine, poised to overcome existing limitations and unlock transformative therapeutic potential.

1. INTRODUCTION

Nanoparticles are ultra-small particles ranging from 1 to 100 nm in size. Due to their tiny size and high surface area, they possess unique physical, chemical, and biological properties that differ significantly from their bulk counterparts. These properties make nanoparticles powerful tools in various scientific and industrial fields, especially in **biomedicine and drug delivery**. One of the main **advantages of nanoparticles** is their ability to interact at the cellular and molecular levels. They can penetrate biological

Copyright: © Author 2026 by the Author. *International Journal of Pharmaceutical Research and Medicinal Plants* Published by **Informative Journals** (Jadoun Science Publishing Group India). This article is an open access article distributed under the terms and conditions of the CC BY-NC-ND 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/)

membranes, protect drugs from premature degradation, and be engineered to release drugs in a controlled or targeted manner. Nanoparticles can improve drug solubility, stability, and bioavailability, which is especially useful for drugs that are poorly absorbed or quickly cleared from the body (De Jong & Borm, 2008). Additionally, nanoparticles can reduce side effects by delivering medication directly to the diseased site, minimizing damage to healthy tissues. Due to these benefits, **nanoparticles have found applications** in numerous areas such as cancer therapy, vaccine delivery, imaging, diagnostics, antimicrobial treatments, and gene therapy. Their role in personalized medicine is also growing, as they can be designed to match a patient's specific biological needs. Among the different types of nanoparticles, **polymeric nanoparticles** have gained significant attention in recent years (Sánchez et al., 2020).

These are nanoparticles made from natural or synthetic polymers such as PLGA (poly(lactic-co-glycolic acid)), chitosan, PEG (polyethylene glycol), and polylactic acid. These polymers are biodegradable, biocompatible, and can be easily modified to suit various drug delivery needs. The **advantages of polymeric nanoparticles** include their ability to encapsulate both hydrophilic (water-loving) and hydrophobic (water-repelling) drugs, provide sustained or stimuli-responsive release, and avoid recognition and clearance by the immune system. Their surfaces can be modified with ligands to achieve targeted delivery to specific tissues or cells, such as cancer cells or infected tissues .In the **medical field,** polymeric nanoparticles are widely studied for delivering drugs in a safer, more effective, and more targeted manner. They are being explored for the treatment of cancer, viral and bacterial infections, inflammatory diseases, neurological disorders, and more (Couvreur, 2013). Despite their many benefits, challenges such as large-scale production, regulatory hurdles, and long-term safety need to be addressed for broader clinical use. As a result of these advantages, polymeric nanoparticles are attracting significant attention for intelligent drug-delivery designs and will become increasingly vital as more innovative therapeutic cargo and treatments develop .Effective polymeric nanoparticles must be designed to migrate a myriad of biological roadblocks throughout both the extracellular and intracellular environments.

These roadblocks are often specific to a particular drug, delivery route, disease, or endogenous target. For example, the challenges associated with delivering low molecular weight drugs, which include solubility, toxicity, and controlled release, are significantly different to the delivery of larger therapeutics such as proteins or nucleic acids, which generally require enhanced stability and targeted release at specific regions within a cell. Thus, understanding how nanoparticles interact with each biological barrier, and which barriers are necessary to mitigate for a given disease/treatment, is crucial to designing highly efficient polymeric nanoparticles for drug delivery. There has been an immense research effort over the last twenty years to develop polymeric nanoparticles that can more effectively respond to these biological challenges and thus optimize therapeutic efficacy.

This research has yielded many success stories, one of which is Abraxane, an albumin-bound paclitaxel formulation that was approved by the FDA in 2005. This nanoparticle is based on the conjugation of paclitaxel, an anti-cancer drug, with albumin, and yields superior pharmacokinetics, improved tumor inhibition and reduced side effects compared to free paclitaxel (Begines et al., 2020a). More recently, injectable formulations have been approved to prolong the release of drugs for treatment of HIV (Apretude) and Osteoporosis (Zilretta). Furthermore, Genexol-PM, a paclitaxel-loaded polymeric micelle, was approved in Korea in 2007 for the treatment of breast, lung and pancreatic cancer. As well as these commercial products, polymeric nanoparticles represent many drug-delivery designs currently in early- and late-stage clinical trials. Polymeric nanoparticles (PNPs) are nanoscale carriers, typically ranging from 10 to 1000 nm, engineered from natural or synthetic polymers to encapsulate or adsorb therapeutic agents. These nanoparticles are classified into nanospheres, where drugs are uniformly dispersed within a polymer matrix, and nanocapsules, which consist of a polymeric shell surrounding a drug-loaded core .Polymeric nanoparticles (PNPs) have emerged as a revolutionary drug delivery platform, offering transformative solutions to longstanding challenges in medicine. Their significance stems from their unique ability to

enhance drug efficacy while minimizing adverse effects. Conventional drug delivery systems often suffer from poor bioavailability, rapid clearance, and non-specific distribution, leading to suboptimal therapeutic outcomes and unwanted side effects. PNPs address these limitations by encapsulating drugs within biocompatible polymer matrices, protecting them from degradation and enabling controlled release over extended periods(Beach et al., 2024). This capability is particularly valuable for drugs with narrow therapeutic windows or those prone to enzymatic breakdown .A key advantage of PNPs is their ability to facilitate targeted drug delivery, improving precision in treating diseases such as cancer. Passive targeting leverages the enhanced permeability and retention (EPR) effect, where nanoparticles accumulate preferentially in tumor tissues due to their leaky vasculature. Active targeting further enhances specificity by conjugating ligands (e.g., antibodies, peptides) to the nanoparticle surface, enabling selective binding to overexpressed receptors on diseased cells. This targeted approach reduces systemic toxicity and enhances therapeutic efficiency. Additionally, PNPs can overcome biological barriers, such as the blood-brain barrier (BBB), enabling drug delivery to previously inaccessible sites like the central nervous system. Beyond small-molecule drugs, PNPs are versatile carriers for macromolecules, including proteins, nucleic acids (siRNA, mRNA), and even hydrophobic-hydrophilic drug combinations. Their tunable polymer composition allows for stimuli-responsive behavior, where drug release is triggered by microenvironmental cues like pH, temperature, or enzymes—ideal for site-specific therapy. The clinical success of formulations like Abraxane® (albumin-bound paclitaxel) and Onpattro® (lipid-polymer siRNA delivery) underscores their real-world impact(Vijaykumar et al., 2014). With ongoing advancements in polymer science and nanotechnology, PNPs continue to pave the way for next-generation therapeutics, offering safer, more effective, and personalized treatment options. Polymeric nanoparticles (PNPs) offer significant advantages over traditional drug delivery systems, such as oral tablets, injections, and liposomal formulations, by overcoming critical pharmacological limitations. One of their most notable benefits is enhanced drug bioavailability. Many therapeutic compounds, particularly hydrophobic drugs and biologics, suffer from poor solubility and rapid degradation in the gastrointestinal tract or bloodstream. PNPs encapsulate these drugs, protecting them from enzymatic degradation and improving their dissolution properties, thereby increasing systemic absorption and therapeutic efficacy(Kumari et al., 2010).

Another major advantage is the ability to achieve controlled and sustained drug release. Conventional formulations often lead to rapid drug clearance, requiring frequent dosing and resulting in fluctuating plasma concentrations. In contrast, polymeric nanoparticles can be engineered to release drugs gradually over hours, days, or even weeks, depending on the polymer's degradation rate (e.g., PLGA for long-term release). This reduces dosing frequency, enhances patient compliance, and maintains therapeutic drug levels within the optimal range, minimizing toxicity(Wu et al., 2020). Perhaps the most transformative feature of PNPs is their targeted delivery capability. Unlike conventional drugs, which distribute non-specifically throughout the body, PNPs can passively accumulate in diseased tissues (e.g., tumors via the EPR effect) or actively target specific cells through surface modifications with ligands like antibodies, peptides, or aptamers.

This precision minimizes off-target effects, reduces systemic toxicity, and enhances drug potency at the desired site. Additionally, PNPs enable delivery across biological barriers(e.g., blood-brain barrier, mucosal membranes) that are typically impermeable to standard drugs. Their versatility extends to co-delivery of multiple therapeutics (e.g., chemotherapeutic drugs with siRNA) and stimuli-responsive release(e.g., pH- or temperature-triggered drug activation in tumors). With successful clinical applications like Abraxane® and Onpattro®, PNPs demonstrate superior performance over conventional systems, offering a smarter, safer, and more effective approach to modern medicine(Jawahar & Meyyanathan et al., 2012).





Fig:1-Overview of polymeric nanoparticles as multifunctional drug delivery systems integrating therapeutic agents for targeted, sustained, and controlled release across various biomedical applications(Begines et al., 2020b).

Polymeric nanoparticles (PNPs) offer distinct advantages over other nanocarriers like liposomes, micelles, and inorganic nanoparticles, making them a versatile choice for drug delivery. Compared to liposomes which have excellent biocompatibility but suffer from stability issues and premature drug leakage—PNPs provide superior structural integrity, controlled drug release, and the ability to encapsulate both hydrophilic and hydrophobic drugs. While polymeric micelles are effective for solublizing hydrophobic drugs, their instability at low concentrations limits their utility, whereas PNPs maintain their structure and offer higher drug-loading capacity(Castro et al., 2022). In contrast to inorganic nanoparticles (e.g., gold or iron oxide), which provide unique diagnostic and therapeutic functionalities but raise long-term toxicity concerns due to non-degradability, PNPs are biodegradable and more easily functionalized for targeted delivery. Although each nanocarrier has its niche—liposomes for mRNA vaccines, micelles for paclitaxel delivery, and inorganic nanoparticles for imaging and hyperthermia—PNPs stand out for their balanced combination of tunable drug release, high stability, and adaptability to diverse therapeutic needs, making them a preferred platform for advanced drug delivery applications(Crucho & Barros et al., 2017)

WORKFLOW



2. POLYMERIC NANOPARTICLES

2.1 TYPES OF POLYMERS

Polymeric nanoparticles can be fabricated using either natural or synthetic polymers, with natural polymers like chitosan, alginate, gelatin, and hyaluronic acid offering distinct advantages for drug delivery applications due to their inherent biocompatibility, biodegradability, and low immunogenicity(Crucho & Barros, 2017b). Chitosan, a cationic polysaccharide derived from chitin, exhibits mucoadhesive properties and can enhance drug absorption across epithelial barriers, making it particularly useful for oral and nasal delivery systems. Alginate, an anionic polysaccharide from brown algae, forms gentle gel-like nanoparticles under mild conditions, ideal for encapsulating sensitive biomolecules like proteins and peptides. Gelatin, obtained from collagen hydrolysis, provides excellent biodegradability and has been widely used in controlled release formulations, while its modifiable functional groups allow for easy surface conjugation(Bhatia, 2016). Hyaluronic acid, a glycosaminoglycan naturally present in extracellular matrices, offers active targeting capabilities through its affinity for CD44 receptors overexpressed in cancer cells and inflamed tissues. These natural polymers not only facilitate drug encapsulation and protection but also often exhibit intrinsic therapeutic properties, such as chitosan's antimicrobial activity or hyaluronic acid's wound-healing potential, making them particularly valuable for developing multifunctional nanomedicines with enhanced therapeutic efficacy and reduced side effects. Synthetic polymers have become the cornerstone of advanced polymeric nanoparticle systems due to their precisely tunable properties and reproducible manufacturing. Among the most widely used, PLGA (poly(lactic-co-glycolic acid)) stands out for its excellent biocompatibility and controllable degradation rate, which can be finely adjusted by varying the lactide-to-glycolide ratio to achieve drug release profiles ranging from days to months.

Its FDA-approved status for various medical applications makes it particularly valuable for controlled drug delivery. PLA (polylactic acid), a related polyester, offers slower degradation kinetics and higher mechanical strength, though with less flexibility in degradation rate modulation compared to PLGA. PEG (polyethylene glycol) is frequently incorporated as a surface coating to confer "stealth" properties, significantly prolonging circulation time by reducing opsonization and reticuloendothelial system clearance(Banik et al., 2016). PCL (polycaprolactone), with its exceptionally slow degradation rate (up to years), finds particular utility in long-term implantable drug delivery systems. Beyond these conventional synthetic polymers, stimuli-responsive polymers represent a revolutionary advancement in smart drug delivery. pH- sensitive polymers, such as poly(β-amino esters), undergo structural changes in the acidic tumor microenvironment or cellular endosomes, enabling precise site-specific drug release. Temperature-sensitive polymers like poly(N-isopropylacrylamide) exhibit reversible phase transitions at physiological temperature ranges, allowing for thermally triggered drug delivery. Redox-sensitive polymers containing disulfide bonds rapidly degrade in the high glutathione concentration of cancer cells, facilitating intracellular drug release. These intelligent materials respond to specific pathological signals or externally applied triggers, creating opportunities for highly sophisticated, spatiotemporally controlled therapeutic systems that maximize drug efficacy while minimizing off-target effects. The combination of synthetic polymers' reliability with stimuli-responsive systems precision represents the cutting edge of targeted nanomedicine development(Vauthier & Bouchemal, 2009).

2.2 FABRICATION METHOD

The production of polymeric nanoparticles (PNPs) involves various techniques, each with distinct advantages and limitations in terms of scalability, reproducibility, drug-loading efficiency, and particle size control(Rane et al., 2018a). Below, we explore the key methods and their critical aspects.




Fig:3-Various method involved in fabrication of PNPs

1. Emulsion-Solvent Evaporation

This widely used method involves dissolving the polymer and drug in an organic solvent (e.g., dichloromethane), emulsifying it in an aqueous phase containing a stabilizer (e.g., PVA), and then evaporating the solvent to form solid nanoparticles. The advantages include high encapsulation efficiency, suitable for hydrophobic drugs, scalable for industrial production. Limitation includes required surfactants, residual solvent removal needed, and particle size depends heavily on homogenization energy(G. Nava-Arzaluz et al., 2012).

2. Nanoprecipitation (Solvent Displacement Method)

A simple and rapid technique where a polymer solution is injected into a non-solvent (e.g., water), causing spontaneous nanoparticle formation due to interfacial deposition. The Advantages are no high-energy mixing required, produces small and uniform particles (~50–300 nm), suitable for lab-scale synthesis. Some Limitations are poor encapsulation of hydrophilic drugs, limited control over particle size distribution(Shinde & More, n.d.).

3. Polymerization Techniques

There are two techniques for polymerization which includes, Emulsion polymerization and Interfacial polymerization. In emulsion Polymerization, monomers are polymerized in an aqueous phase with surfactants, forming nanoparticles in situ which is useful for synthetic polymers like poly(alkyl cyanoacrylates).Where as in interfacial Polymerization the two reactive monomers meet at an oil-water interface, forming nanocapsules which is ideal for encapsulating fragile biomolecules. The advantages and disadvantages are good control over particle size and polymer properties, potential toxicity from unreacted monomers, complex purification steps respectively(C. Liu et al., 2020).

4. Supercritical Fluid Technology (SCF)

Uses supercritical CO_2 as an environmentally friendly alternative to organic solvents. Techniques include supercritical antisolvent (SAS) precipitation and rapid expansion of supercritical solutions (RESS). The advantages are no solvent residues, narrow size distribution, suitable for thermolabile drugs. Limitations are High equipment cost, limited polymer compatibility(Sheth et al., 2012).

5. Microfluidics-Based Synthesis

A cutting-edge approach where fluids are precisely mixed in microchannels to form nanoparticles with highly controlled properties(Li et al., 2021).The advantages are excellent reproducibility, tunable size (10–500 nm), ideal for complex formulations (e.g., lipid-polymer hybrids).Where as limitations are Low throughput, challenges in large-scale manufacturing(Khizar et al., 2022).

Table:1-Comparison of different type of fabrication methods

Fabrication Method	Scalability	Reproducibility	Particle Size Control	Best For	Efficiency
Emulsion-Solvent Evaporation	High	Moderate-High	Moderate (100–500 nm)	Hydrophobic drugs, PLGA NPs	60-75%
Nanoprecipitation	Moderate	High	Good (50–300 nm)	Small-scale, lipophilic drugs	80-90%
Polymerization	Moderate-High	Moderate	Good (50–400 nm)	In-situ synthesis of nanospheres	65-80%
Supercritical Fluids	Low-Moderate	High	Excellent (20–200 nm)	Solvent-free, uniform NPs	50-70%
Microfluidics	Low	Very High	Excellent (10–500 nm)	Precision-engineered NPs	70-85%

3. PHARMACOKINETICS STUDIES

Polymeric nanoparticles employ two primary drug incorporation strategies: encapsulation within the polymer matrix or surface adsorption. Encapsulation, typically used for hydrophobic drugs, provides superior drug protection and controlled release, while adsorption allows for easier loading of hydrophilic compounds but may lead to faster drug leakage. Several critical factors influence drug loading efficiency, including polymer-drug compatibility (hydrophobic drugs pair best with hydrophobic polymers like PLGA), the chosen fabrication method (emulsion techniques generally offer higher encapsulation yields than nanoprecipitation), and specific drug-polymer interactions(Zur Mühlen et al., 1998). Drug release kinetics are governed by three main mechanisms ie, diffusion through the polymer matrix, polymer degradation rate, and in stimuli-responsive systems, environmental triggers like pH or temperature changes. These release profiles can be tailored for either sustained delivery (using slow-degrading polymers for chronic conditions) or burst release (ideal for vaccines or acute treatments). The design strategy depends on the therapeutic requirements - sustained release maintains therapeutic levels over extended periods, while burst release ensures rapid drug availability. Advanced systems now combine these approaches, using stimuli-responsive polymers to create "smart" nanoparticles that release drugs only at specific target sites, maximizing therapeutic efficacy while minimizing side effects(Owens & Peppas, 2006). These technological advances continue to expand the applications of polymeric nanoparticles in precision medicine.

4. ENCAPSULATION VS ADSORPTION OF DRUGS IN POLYMERIC NANOPARTICLES

Polymeric nanoparticles utilize two distinct approaches for drug incorporation: encapsulation and adsorption, each with unique advantages and limitations. Encapsulation involves the physical entrapment of drug molecules within the polymer matrix during nanoparticle formation, creating a protected reservoir system. This method is particularly advantageous for hydrophobic drugs, as it provides high loading capacity, shields the drug from degradation, and enables controlled release kinetics. The encapsulation efficiency depends on

factors like polymer-drug compatibility, with hydrophobic polymers (e.g., PLGA, PCL) showing superior encapsulation for lipophilic compounds(Cheow & Hadinoto, 2011). In contrast, adsorption relies on the surface attachment of drug molecules to pre-formed nanoparticles through electrostatic interactions, hydrogen bonding, or hydrophobic forces. While adsorption facilitates easier loading of hydrophilic or charged molecules and allows for faster drug release, it may result in premature drug leakage and lower loading capacity compared to encapsulation(Cohen et al., 2000). The choice between these strategies depends on the drug's physicochemical properties, desired release profile, and therapeutic application - encapsulation being preferred for sustained delivery systems, while adsorption may be suitable for rapid-onset therapies or when maintaining drug stability is less critical. Recent advances have enabled hybrid approaches that combine both encapsulation and adsorption to achieve optimized drug loading and tailored release profiles for complex therapeutic needs (Pinto Reis et al., 2006).

4.1 SURFACE MODIFICATION AND FUNCTIONALIZATION STRATEGIES FOR POLYMERIC NANOPARTICLES

The surface engineering of polymeric nanoparticles has emerged as a transformative approach to overcome biological barriers and achieve targeted drug delivery. PEGylation remains the gold standard for conferring stealth properties, where polyethylene glycol chains (typically 2-20 kDa) form a hydrophilic corona that reduces opsonization and extends circulation half-life through steric stabilization(Mauri et al., 2017). Recent advances in PEG chemistry have introduced branched architectures and cleavable linkages (pH-, enzyme-, or redox-sensitive) that address limitations of traditional linear PEG, including the accelerated blood clearance phenomenon observed in some patients. Beyond PEGylation, alternative stealth polymers such as poly(2-oxazoline) and zwitterionic materials are gaining attention for their reduced immunogenicity and superior protein resistance. For active targeting, a diverse array of ligands including monoclonal antibodies (e.g., trastuzumab for HER2+ cancers), engineered antibody fragments (scFv, nanobodies), and peptide motifs (RGD, TAT) enable receptor-specific delivery, while aptamers like AS1411 offer advantages of small size and thermal stability. Small molecule targeting approaches utilizing folate, biotin, or carbohydrate moieties provide additional options for tissue-specific accumulation. Surface charge engineering plays a critical role in biodistribution, where cationic nanoparticles (potential +15 to +25 mV) facilitate mucosal adhesion and blood-brain barrier penetration through adsorptive transcytosis, while anionic surfaces exhibit reduced nonspecific interactions and improved tumor penetration(Choi et al., 2003). Emerging multi-functional systems combine these approaches through innovative designs such as charge-switching nanoparticles that transition from neutral/anionic during circulation to cationic at target sites, or "masked" ligands that only expose targeting moieties in response to disease-specific stimuli. Advanced characterization techniques including X-ray photoelectron spectroscopy, time-of-flight secondary ion mass spectrometry, and surface plasmon resonance are essential for verifying surface modifications and quantifying ligand density. As the field progresses, bioinspired approaches incorporating cell membrane coatings and biomimetic surfaces are showing promise for enhanced immune evasion and tissue homing. However, challenges remain in scaling up production of surface-engineered nanoparticles while maintaining batch-to-batch consistency and meeting regulatory requirements for novel excipients. Future directions point toward increasingly sophisticated systems featuring dynamic, environmentally responsive surfaces capable of adapting their properties in real-time to optimize drug delivery, as well as personalized approaches that tailor surface modifications to individual patient characteristics. These surface engineering strategies are transforming polymeric nanoparticles from simple drug carriers to intelligent, multifunctional delivery systems with precisely controlled interactions in biological environments .This comprehensive surface modification approach enables fine-tuning of nanoparticle pharmacokinetics, biodistribution, and cellular uptake, addressing critical challenges in drug delivery ranging from overcoming biological barriers to achieving cell-specific targeting(Ahmed et al., 2021). The continued development of novel surface engineering techniques, combined with improved analytical methods and manufacturing processes, promises to further enhance the

therapeutic potential of polymeric nanoparticles across a wide range of medical applications. As our understanding of nanoparticle-biological interactions deepens, surface modification strategies are evolving from empirical approaches to rationally designed systems based on computational modeling and artificial intelligence, paving the way for next-generation nanomedicines with unprecedented precision and efficacy(Patil et al., 2009). These advances position surface-engineered polymeric nanoparticles at the forefront of targeted drug delivery, with growing clinical impact in oncology, neurology, and regenerative medicine.




Fig:4 Polymeric Nanoparticles for Targeted Drug Delivery: Design, Biological Journey, and Therapeutic Action

5. BIOLOGICAL CHALLENGES AND THE PROTEIN CORONA PHENOMENON

A pivotal, yet often underappreciated, barrier to the clinical translation of polymeric nanoparticles is their dynamic interaction with the biological milieu, culminating in the formation of a “protein corona” (Kopac, 2021).Upon intravenous administration, PNPs are immediately immersed in a complex biological fluid, leading to the rapid and spontaneous adsorption of a layer of plasma proteins and other biomolecules onto their surface. This protein corona does not merely represent a passive coating; it fundamentally redefines the nanoparticle's biological identity, effectively masking the meticulously engineered surface properties, including targeting ligands such as antibodies, peptides, or aptamers. This obfuscation can severely compromise active targeting strategies, rendering them ineffective as the nanoparticle's interactions with cell receptors are dictated by the corona's composition rather than the underlying ligand. Furthermore, the corona dictates the subsequent biological fate of the PNP, influencing its cellular uptake mechanisms, biodistribution profile, and propensity for clearance by the mononuclear phagocyte system (MPS)(Heidarzadeh et al., 2023). The composition of the corona is highly variable and depends on the nanoparticle's original surface chemistry, size, and shape, as well as individual patient factors, introducing a significant element of unpredictability and batch-to-batch variability that complicates clinical outcomes. In response to this challenge, current research is focused on developing sophisticated surface engineering strategies to mitigate or control corona formation. These include the use of ultra-hydrophilic and neutrally charged "stealth" coatings beyond traditional PEG, such as poly(2-oxazoline)s and zwitterionic polymers, which exhibit superior protein resistance. An alternative, innovative approach involves the pre-formation of a "synthetic" or "custom" corona with specific, functional proteins to deliberately steer the nanoparticle towards a desired biological pathway, thereby transforming a potential obstacle into a tool for precision delivery. Addressing the protein corona is not merely an optimization step but a fundamental prerequisite for designing PNPs that perform predictably and effectively in the complex human physiological environment(Neagu et al., 2017).

6. PHARMACODYNAMICS STUDIES

The release profile of encapsulated drugs from polymeric nanoparticles is governed by complex, interrelated mechanisms that can be tailored for specific therapeutic needs. Three primary mechanisms dominate drug release kinetics are (1)diffusion-controlled release, where drug molecules gradually migrate through the polymer matrix - this mechanism predominates in hydrophobic polymers with low degradation rates are (2)erosion/degradation-controlled release, where hydrolytic or enzymatic breakdown of polymer chains (e.g., ester hydrolysis in PLGA) governs release rates, particularly important for sustained delivery systems; and (3) stimuli-responsive release, triggered by microenvironmental cues like pH shifts in tumors (pH 6.5-7.0), elevated glutathione levels in cancer cells (redox-sensitive), or external triggers like temperature or light(Kamaly et al., 2016). The release kinetics follow characteristic patterns - initial burst release from surface-associated drug, followed by diffusion-mediated release, and finally degradation-controlled release as the polymer matrix breaks down. Mathematical models (Higuchi, Korsmeyer-Peppas) help quantify these processes, where release exponents indicate whether diffusion (n=0.5) or erosion (n=1.0) dominates. Smart engineering allows precise temporal control - from immediate release (hours) for acute treatments to prolonged release (weeks-months) for chronic conditions. Current advances focus on multi-stage release systems combining these mechanisms, such as nanoparticles providing initial rapid release for immediate effect followed by sustained release for prolonged therapy, all while responding to biological triggers for site-specific delivery. These sophisticated release profiles are revolutionizing treatment paradigms across oncology, infectious diseases, and regenerative medicine(Bohrey et al., 2016).

7. FACTORS AFFECTING DRUG LOADING EFFICIENCY IN POLYMERIC NANOPARTICLES

The drug loading efficiency of polymeric nanoparticles is influenced by multiple interrelated factors that must be carefully optimized for each therapeutic applications are,

1. Polymer-Drug Compatibility

The physicochemical compatibility between the drug and polymer is fundamental. Hydrophobic drugs (e.g., paclitaxel, curcumin) exhibit superior loading in hydrophobic polymers like PLGA or PCL due to favourable partitioning. For hydrophilic drugs (e.g., proteins, nucleic acids), hydrophilic polymers such as chitosan or alginate are preferred, often requiring additional strategies like ion pairing or chemical conjugation. Amphiphilic drugs present unique challenges and may require polymer blends or surface-modified carriers. Recent advances include the development of zwitterionic polymers that can accommodate both hydrophobic and hydrophilic moieties(J. Liu et al., 2004).

2. Fabrication Method Selection

The nanoparticle production technique significantly impacts loading capacity are emulsion-solvent evaporation provides excellent encapsulation (60-90%) for lipophilic drugs but may denature biologics ,nanoprecipitation achieves moderate loading (30-70%) for small molecules but poor retention of macromolecules ,spray drying enables high throughput but may cause thermal degradation ,microfluidic methods offer precise control but currently have limited scalability ,emerging techniques like electrohydrodynamic processes show promise for high-efficiency loading of sensitive biomolecules(Rane et al., 2018b).

3. Drug-Polymer Interactions

The nature of intermolecular forces critically affects both loading and release are hydrophobic interactions dominate in PLGA/drug systems ,ionic interactions are exploited in chitosan-based carriers ,hydrogen bonding influences protein loading in gelatin nanoparticles,π-π stacking can enhance loading of aromatic compounds ,excessive drug-polymer affinity can create "retention effects" that impede complete drug release, requiring careful balance(Bookwala & Wildfong, 2023).

4. Particle Characteristics

The Size are chosen from Sub-100nm particles have higher surface area but reduced core volume ,porosity includes controlled porosity can increase and capacity while maintaining structure ,the Surface charge are zeta potential affects both loading and stability and morphology of particles are core-shell vs matrix structures offer different loading advantages .Understanding these multifactorial relationships enables rational design of nanoparticles with precisely controlled drug loading characteristics tailored to specific therapeutic requirements. Ongoing research focuses on developing predictive models and high-throughput screening methods to accelerate formulation optimization(Wang et al., 2007).

8. RECENT ADVANCES AND EMERGING TRENDS

The field of polymeric nanoparticles has witnessed transformative innovations, particularly in the development of smart, stimuli-responsive systems that enable precise spatiotemporal drug release. These advanced nanoparticles respond to biological cues such as pH gradients (e.g., tumor microenvironment), redox conditions (e.g., high glutathione in cancer cells), or external triggers (light, ultrasound), allowing for on-demand drug delivery(W. S. Khan et al., 2025). Theranostic nanoparticles, integrating therapy and diagnostics, now incorporate contrast agents (quantum dots, iron oxide) for real-time imaging and treatment monitoring. Another breakthrough is the 3D printing of polymeric nanoparticles, which enables precise control over size, shape, and drug-loading parameters, facilitating personalized medicine. (Vora et al., 2023)AI-driven design is revolutionizing formulation optimization, using machine learning to predict polymer-drug compatibility, release kinetics, and in vivo behavior, significantly reducing trial-and-error experimentation. Additionally, green synthesis approaches are gaining traction, with researchers developing biodegradable, eco-friendly polymers (e.g., plant-derived polysaccharides) and solvent-free fabrication methods (supercritical CO_2) to enhance sustainability(Jain et al., 2014).

8.1. Biohybrid and Biomimetic Nanoparticles: Leveraging Biological Complexity

A paradigm shift in PNP design is emerging with the development of biohybrid and biomimetic systems, which seek to circumvent biological barriers by co-opting natural biological structures and pathways. Rather than relying solely on synthetic chemistry to evade immune detection, researchers are now fabricating PNPs cloaked in natural cell membranes. This approach involves the extraction and fusion of lipid bilayers from specific cells such as red blood cells (RBCs), leukocytes, or cancer cells onto the surface of synthetic polymeric cores(Harun-Ur-Rashid et al., 2023). RBC membrane-coated PNPs, for instance, display "self" markers like CD47 that inhibit phagocytosis by macrophages, conferring dramatically prolonged circulation half-lives that can surpass even the most advanced stealth polymers. Conversely, leukocyte membrane coatings endow PNPs with the innate ability to target inflamed tissues and penetrate biological barriers like the blood-brain barrier by mimicking the adhesion and transmigration processes of immune cells. In oncology, homotypic targeting is achieved by coating PNPs with membranes derived from the patient's own cancer cells, exploiting their inherent affinity for self-progenitor cells within a tumor mass. This biomimetic strategy represents a significant leap beyond traditional ligand-receptor targeting, as it presents a complex, biologically authentic surface that can interact with the host environment in a more sophisticated and multi-faceted manner, thereby enhancing targeting precision, improving biocompatibility, and reducing immunogenic responses(Ighodaro et al., 2024).

8.2. The Role of Artificial Intelligence and In Silico Modeling

The complexity of PNP design, governed by a multitude of interdependent variables, is increasingly being untangled through the application of artificial intelligence (AI) and machine learning (ML). Moving beyond simple optimization, AI-driven platforms are now capable of predicting fundamental properties such as polymer-drug compatibility, which dictates encapsulation efficiency and release kinetics, by analyzing vast chemical datasets(Sinisi, 2021). Machine learning models can process experimental parameters from the

fabrication process including polymer molecular weight, solvent choice, surfactant concentration, and homogenization speed—to predict and optimize resulting nanoparticle characteristics like size, zeta potential, and polydispersity index with remarkable accuracy, drastically reducing the traditional "trial-and-error" experimentation cycle. Furthermore, the emerging concept of a "digital twin"—a comprehensive computational model of a PNP that simulates its behavior in a virtual physiological environment holds immense promise. These in silico models can integrate data on PNP properties with known physiological parameters to forecast in vivo pharmacokinetics, biodistribution, and even therapeutic efficacy before a single nanoparticle is synthesized(Yash et al., 2025). This paradigm not only accelerates the development timeline but also enables a more rational and resource-efficient design process, paving the way for highly personalized nanomedicine where PNP formulations could be tailored and virtually tested against a patient-specific digital avatar.

8.3. CLINICAL TRANSLATION AND COMMERCIAL LANDSCAPE

The journey of polymeric nanoparticles from laboratory innovation to clinical application represents the ultimate validation of their therapeutic potential. While the path is fraught with challenges, several PNPs have successfully navigated the regulatory landscape, offering tangible clinical benefits. The most prominent example remains Abraxane® (albumin-bound paclitaxel), which leverages endogenous albumin pathways to enhance tumor targeting and eliminate the need for toxic solvents like Cremophor EL, thereby significantly improving the safety profile of paclitaxel chemotherapy. Beyond this flagship product, other notable successes include Genexol-PM, a paclitaxel-loaded polymeric micelle approved in South Korea for breast and lung cancer, which demonstrates superior tumor accumulation through the EPR effect, and Onpattro® (patisiran), a lipid nanoparticle formulation for siRNA delivery that, while not a pure PNP, shares core principles with polymer-based systems and validates the broader nanocarrier approach for nucleic acid therapeutics. These successes, however, belie the significant attrition rate of PNP formulations in clinical development(Vargason et al., 2018). A critical analysis reveals that many promising candidates fail in late-stage trials due to a confluence of factors. A primary reason is the lack of a substantial therapeutic advantage over existing standard-of-care treatments, where improved efficacy fails to materialize in heterogeneous human patient populations. Furthermore, unexpected immunogenic responses, such as complement activation-related pseudoallergy (CARPA) or the accelerated blood clearance (ABC) phenomenon associated with repeated dosing of PEGylated nanoparticles, can halt development(M. N. Khan, 2020). Crucially, the translation from robust efficacy in murine models to humans is often hampered by the oversimplification of animal models, which fail to fully recapitulate the complexity and variability of human tumors, particularly the heterogeneity of the EPR effect. This translational gap is compounded by the formidable challenge of scaling up laboratory synthesis methods such as nanoprecipitation or microfluidics to industrial-scale Good Manufacturing Practice (GMP) production. Maintaining stringent control over critical quality attributes like particle size, polydispersity index, and drug loading efficiency at a large scale is non-trivial and economically demanding, often leading to batch-to-batch variations that can impact clinical outcomes. Therefore, the future clinical success of PNPs hinges not only on scientific innovation but also on a deliberate focus on developing robust, scalable, and economically viable manufacturing processes alongside clinical trial designs that can genuinely demonstrate a superior risk-benefit profile in well-defined patient populations(Hua et al., 2018).

9. CONCLUSION AND FUTURE PERSPECTIVES

In conclusion, polymeric nanoparticles have unequivocally established themselves as a cornerstone of modern drug delivery, evolving from simple inert carriers to sophisticated, multifunctional platforms capable of targeted, stimuli-responsive, and theranostic applications. This review has delineated the journey from their fundamental building blocks biocompatible natural and synthetic polymers and the fabrication techniques that define their physical properties, to the advanced engineering of their surfaces and release kinetics aimed at overcoming biological barriers(Patel et al., 2012). The clinical success of formulations like

Abraxane® and Genexol-PM underscores the transformative potential of this technology, validating years of intensive research and development. However, the path from laboratory innovation to widespread clinical adoption remains fraught with significant challenges. The persistent issues of scalable manufacturing, batch-to-batch reproducibility, and a comprehensive understanding of long-term biocompatibility continue to impede progress. Furthermore, the biological complexity of the *in vivo* environment, epitomized by the protein corona phenomenon and the heterogeneity of human pathophysiology, reveals a critical gap between pre-clinical promise and clinical efficacy that must be bridched.

Looking forward, the future of polymeric nanoparticles lies in embracing complexity and intelligence across multiple fronts. First, the next generation of PNPs must be inherently "smarter." This involves developing multi-stage, adaptive systems that can sequentially overcome barriers: for instance, particles that maintain a stealthy, neutral charge during circulation, then become positively charged for enhanced tissue penetration, and finally, release their payload only upon encountering a specific intracellular trigger like high glutathione levels. Second, the paradigm of biomimicry must be fully leveraged(Gagliardi et al., 2021). Biohybrid nanoparticles, cloaked in natural cell membranes, offer a revolutionary approach to achieving superior immune evasion and tissue-specific homing, effectively tricking the body's own defense mechanisms. Third, the integration of artificial intelligence and machine learning will be indispensable. Moving beyond heuristic formulation, AI-driven predictive modeling and the creation of "digital twins" for nanoparticles will accelerate the rational design of PNP systems, optimizing their properties *in silico* before synthesis and dramatically reducing development timelines. Finally, a concerted focus on translational science is paramount. Future research must prioritize robust, scalable, and economically viable Good Manufacturing Practice (GMP)-compliant production methods from the outset(Yash et al., 2025). Simultaneously, clinical trials need to be designed with a sharper focus on patient stratification, leveraging biomarkers to identify individuals most likely to benefit from nanotherapeutic interventions. As we stand at the confluence of nanotechnology, bioengineering, and data science, polymeric nanoparticles are poised to usher in a new era of precision medicine, offering truly personalized, effective, and safe therapeutic solutions for some of the most daunting diseases, including cancer, neurodegenerative disorders, and antibiotic-resistant infections. The next decade will undoubtedly witness these innovations transition from compelling proof-of-concept studies to clinically viable therapies that reshape the therapeutic landscape.

REFERENCES:

1. Banik, B. L., Fattahi, P., & Brown, J. L.(2016). Polymeric nanoparticles: The future of nanomedicine. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 8(2), 271–299. https://doi.org/10.1002/WNAN.1364
2. Beach, M. A., Nayanathara , U., Gao, Y., Zhang, C., Xiong , Y., Wang, Y., & Such, G. K.(2024). Polymeric Nanoparticles for Drug Delivery. Chemical Reviews, 124(9), 5505–5616. https://doi.org/10.1021/ACS.CHEMREV.3C00705
3. Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez , G., Merinero, M., Argüelles-Arias, F., & Alcudia, A.(2020). Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials, 10(7), 1403. https://doi.org/10.3390/NANO10071403
4. Bhatia, S.(2016). Nanoparticles Types, Classification, Characterization, Fabrication Methods and Drug Delivery Applications .Natural Polymer Drug Delivery Systems, 33–93. https://doi.org/10.1007/978-3-319-41129-3_2
5. Bohrey, S., Chourasiya, V., & Pandey, A.(2016). Polymeric nanoparticles containing diazepam: Preparation, optimization, characterization, in-vitro drug release and release kinetic study. Nano Convergence, 3(1), 1–7. https://doi.org/10.1186/S40580-016-0061-2

6. Bookwala, M., & Wildfong, P. L. D.(2023). The Implications of Drug-Polymer Interactions on the Physical Stability of Amorphous Solid Dispersions. Pharmaceutical Research, 40(12), 2963–2981. https://doi.org/10.1007/S11095-023-03547-4

7. Castro, K. C. de, Costa, J. M., & Campos, M. G. N.(2022). Drug-loaded polymeric nanoparticles: a review .International Journal of Polymeric Materials and Polymeric Biomaterials, 71(1), 1–13. https://doi.org/10.1080/00914037.2020.1798436

8. Cheow, W. S., & Hadino, K. (2011). Factors affecting drug encapsulation and stability of lipid–polymer hybrid nanoparticles. Colloids and Surfaces B: Biointerfaces, 85(2), 214–220. https://doi.org/10.1016/J.COLSURFB.2011.02.033

9. Choi, S. W., Kim, W. S., & Kim, J. H.(2003). Surface modification of functional nanoparticles for controlled drug delivery. Journal of Dispersion Science and Technology, 24(3–4), 475–487. https://doi.org/10.1081/DIS-120021803

10. Cohen, H., Levy, R. J., Gao, J., Fishbein , I., Kousaev, V., Sosnowski, S., Slomkowski, S., & Golomb, G.(2000). Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Therapy, 7(22), 1896–1905. https://doi.org/10.1038/SJ.GT.3301318

11. Couvreur, P. (2013). Nanoparticles in drug delivery: Past, present and future. Advanced Drug Delivery Reviews, 65(1), 21–23. https://doi.org/10.1016/J.ADDR.2012.04.010

12. 12.Crucho, C. I. C., & Barros, M. T. (2017). Polymeric nanoparticles: A study on the preparation variables and characterization methods. Materials Science and Engineering: C, 80, 771–784. https://doi.org/10.1016/J.MSEC.2017.06.004

13. De Jong, W. H., & Borm , P. J. A. (2008). Drug delivery and nanoparticles: Applications and hazards.International Journal of Nanomedicine,3(2),133–149. https://doi.org/10.2147/IJN.S596

14. G. Nava-Arzaluz, M., Pinon-Segundo, E., Ganem-Rondero, A., & Lechuga-Ballesteros, D.(2012). Single Emulsion-Solvent Evaporation Technique and Modifications for the Preparation of Pharmaceutical Polymeric Nanoparticles. Recent Patents on Drug Delivery & Formulation, 6(3), 209–223. https://doi.org/10.2174/187221112802652633

15. Jain, K., Mehra, N. K., & Jain, N. K.(2014). Potentials and emerging trends in nanopharmacology. Current Opinion in Pharmacology, 15(1), 97–106. https://doi.org/10.1016/J.COPH.2014.01.006

16. Jawahar, N., & Meyyanathan, S. (2012). Polymeric nanoparticles for drug delivery and targeting: A comprehensive review. International Journal of Health & Allied Sciences, 1(4), 217.https://go.gale.com/ps/i.do?p=AONE&sw=w&issn=22784292&v=2.1&it=r&id=GALE%7CA324113001

17. Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016). Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of controlling drug release. Chemical Reviews, 116(4), 2602–2663. https://doi.org/10.1021/ACS.CHEMREV.5B00346

18. Khan, W. S., Asmatulu, E., & Asmatulu, R. (2025). Nanotechnology emerging trends, markets and concerns. Nanotechnology Safety, 1–21. https://doi.org/10.1016/B978-0-443-15904-6.00017-4

19. Khizar, S., Zine, N., Errachid, A., Jaffrezic-Renault, N., & Elaissari, A.(2022). Microfluidic-based nanoparticle synthesis and their potential applications. ELECTROPHORESIS, 43(7–8), 819–838. https://doi.org/10.1002/ELPS.202100242

20. Kumari, A., Yadav, S. K., & Yadav, S. C.(2010). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and Surfaces B: Biointerfaces, 75(1), 1–18. https://doi.org/10.1016/J.COLSURFB.2009.09.001

21. Li, W., Chen, Q., Baby, T., Jin , S., Liu, Y., Yang, G., & Zhao, C. X.(2021). Insight into drug encapsulation in polymeric nanoparticles using microfluidic nanoprecipitation. Chemical Engineering Science, 235, 116468. https://doi.org/10.1016/J.CES.2021.116468

22. Liu, C., Hong, C. Y., & Pan, C. Y. (2020). Polymerization techniques in polymerization-induced self-assembly (PISA).Polymer Chemistry, 11(22), 3673–3689. https://doi.org/10.1039/D0PY00455C

23. Liu, J., Xiao, Y., & Allen, C. (2004). Polymer–drug compatibility: A guide to the development of delivery systems for the anticancer agent, ellipticine. Journal of Pharmaceutical Sciences, 93(1), 132–143. https://doi.org/10.1002/JPS.10533

24. Mauri, E., Papa, S., Masi, M., Veglianese, P., & Rossi, F. (2017). Novel functionalization strategies to improve drug delivery from polymers. Expert Opinion on Drug Delivery, 14(11), 1305–1313. https://doi.org/10.1080/17425247.2017.1285280

25. Patil, Y. B., Toti, U. S., Khdair, A., Ma, L., & Panyam, J.(2009). Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials, 30(5), 859–866. https://doi.org/10.1016/J.BIOMATERIALS.2008.09.056

26. Pinto Reis, C., Neufeld, R. J., Ribeiro, A. J., & Veiga, F. (2006). Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles.Nanomedicine: Nanotechnology,Biology and Medicine, 2(1), 8–21. https://doi.org/10.1016/J.NANO.2005.12.003

27. Rane, A. V., Kanny, K., Abitha, V. K., & Thomas, S. (2018). Methods for Synthesis of Nanoparticles and Fabrication of Nanocomposites. Synthesis of Inorganic Nanomaterials: Advances and Key Technologies, 121–139. https://doi.org/10.1016/B978-0-08-101975-7.00005-1

28. Sánchez, A., Mejía, S. P., & Orozco, J.(2020). Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections. Molecules, 25(16), 3760. https://doi.org/10.3390/MOLECULES25163760

29. Sheth, P., Sandhu, H., Singhal, D., Malick, W., Shah, N., & Serpil Kislalioglu, M.(2012). Nanoparticles in the Pharmaceutical Industry and the Use of Supercritical Fluid Technologies for Nanoparticle Production.Current Drug Delivery, 9(3), 269–284. https://doi.org/10.2174/156720112800389052

30. Shinde, A. J., & More, H. N. (n.d.). Formulation, development and characterization of Simvastatin nanoparticles by solvent displacement method. Retrieved from www.scholarsresearchlibrary.com

31. Vauthier, C., & Bouchemal, K.(2009). Methods for the Preparation and Manufacture of Polymeric Nanoparticles.Pharmaceutical Research, 26(5), 1025–1058. https://doi.org/10.1007/S11095-008-9800-3

32. Vijaykumar, O., Felix Joe, V., & Vishwanath, B. A.(2014). Formulation and evaluation of rivastigmine loaded polymeric nanoparticles. Journal of Chemical and Pharmaceutical Research, 6(10), 556–565.

33. Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P.(2023). Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics, 15(7), 1916. https://doi.org/10.3390/PHARMACEUTICS15071916

34. Wang, X., Hall, J. E., Warren, S., Krom, R., Magistrelli, J. M., Rackaitis, M., & Bohm, G. G. A. (2007). Synthesis, characterization, and application of novel polymeric nanoparticles. Macromolecules, 40(3), 499–508. https://doi.org/10.1021/MA0613739

35. Wu, S., Helal-Neto, E., Matos, A. P. dos S., Jafari, A., Kozempel, J., Silva, Y. J. de A., Serrano-Larrea, C., Alves Junior, S., Ricci-Junior, E., Alexis, F., & Santos-Oliveira, R.(2020). Radioactive polymeric nanoparticles for biomedical application. Drug Delivery, 27(1), 1544–1561. https://doi.org/10.1080/10717544.2020.1837296
36. Zur Mühlen, A., Schwarz, C., & Mehnert, W.(1998). Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism. European Journal of Pharmaceutics and Biopharmaceutics, 45(2), 149–155. https://doi.org/10.1016/S0939-6411(97)00150-1

How to cite this article: Kaviya Priya K, Subashini R, Kamali M.L., Sri Priya E, Naresh Kannan S, Polymeric Nanoparticles for Drug Delivery (2026). *International Journal of Pharmaceutical Research and Medicinal Plants*, *2*(5),60-75. https://doi.org/10.61280/774vgk83

Published by:
Informative Journals
Jadoun Science Publishing Group India